Cargando…
(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
Valbenazine and deutetrabenazine are the only two therapeutic drugs approved for tardive dyskinesia based on blocking the action of vesicular monoamine transporter 2 (VMAT2). But there exist demethylated inactive metabolism at the nine position for both them resulting in low availability, and CYP2D6...
Autores principales: | Wang, Wenyan, Du, Guangying, Lin, Shilan, Liu, Jing, Yang, Huijie, Yu, Dawei, Ye, Liang, Zou, Fangxia, Wang, Hongbo, Zhang, Rui, Tian, Jingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689140/ https://www.ncbi.nlm.nih.gov/pubmed/34950030 http://dx.doi.org/10.3389/fphar.2021.770377 |
Ejemplares similares
-
Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019) -
Association Study of the Complement Component C4 Gene in Tardive Dyskinesia
por: Zai, Clement C., et al.
Publicado: (2019) -
Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019) -
Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis
por: Zai, Clement C., et al.
Publicado: (2018) -
METOCLOPRAMIDE IN TARDIVE DYSKINESIA
por: Hemanani, T.J., et al.
Publicado: (1983)